Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity

GLIA

Volumn 59, Issue 3, 2011, Pages 435-451

  Miyazaki, Ikuko ^a   Asanuma, Masato ^a   Kikkawa, Yuri ^a   Takeshima, Mika ^a   Murakami, Shinki ^a   Miyoshi, Ko ^a   Sogawa, Norio ^a   Kita, Taizo ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KYUSHU NUTRITION WELFARE UNIVERSITY   (Japan)

Author keywords

Dopamine transporter; Methamphetamine; Neuroprotection; Nrf2; Parkinson's disease

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIBODY; DOPAMINE; LEVODOPA; METALLOTHIONEIN I; METALLOTHIONEIN II; QUINONE DERIVATIVE; SCAVENGER; SULPIRIDE; TRANSCRIPTION FACTOR NRF2; VANOXERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; ASTROCYTE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; EMBRYO; GLIA CELL; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; UPREGULATION;

ANIMALS; ASTROCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; DOPAMINE; FREE RADICAL SCAVENGERS; METALLOTHIONEIN; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78751691004     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21112     Document Type: Article

References (54)

1. Asanuma M, Hirata H, Cadet JL. 1998. Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 85: 907-917.
2. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M, Miyoshi K, Murata M. 2010. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol 67: 239-249.
3. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Ogawa N. 2004a. Quinone formation as dopaminergic neuron-specific oxidative stress in pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama 58: 221-233.
4. Asanuma M, Miyazaki I, Higashi Y, Tsuji T, Ogawa N. 2004b. Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Ann NY Acad Sci 1025: 69-75.
5. Asanuma M, Miyazaki I, Ogawa N. 2003. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5: 165-176.
6. Aschner M. 1998. Metallothionein (MT) isoforms in the central nervous system (CNS): Regional and cell-specific distribution and potential functions as an antioxidant. Neurotoxicology 19: 653-660.
7. Cadet JL, Brannock C. 1998. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32: 117-131.
8. Cadet JL, Jayanthi S, Deng X. 2003. Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17: 1775-1788.
9. Castano A, Herrera AJ, Cano J, Machado A. 1998. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70: 1584-1592.
10. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. 2009. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci USA 106: 2933-2938.
11. Chung RS, Adlard PA, Dittmann J, Vickers JC, Chuah MI, West AK. 2004. Neuron-glia communication: Metallothionein expression is specifically up-regulated by astrocytes in response to neuronal injury. J Neurochem 88: 454-461.
12. Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, Asmussen JW, Hidalgo J, Carrasco J, Leung YK, Walker AK, Fung SJ, Dunlop SA, Fitzgerald M, Beazley LD, Chuah MI, Vickers JC, West AK. 2008. Redefining the role of metallothionein within the injured brain: Extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J Biol Chem 283: 15349-15358.
13. Chung RS, Vickers JC, Chuah MI, West AK. 2003. Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury. J Neurosci 23: 3336-3342.
14. Chung RS, West AK. 2004. A role for extracellular metallothioneins in CNS injury and repair. Neuroscience 123: 595-599.
15. Diaz-Corrales FJ, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N. 2005. Rotenone induces aggregation of gamma-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration. Neuroscience 133: 117-135.
16. Dinkova-Kostova AT, Holtzclaw WD, Wakabayashi N. 2005. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 44: 6889-6899.
17. Elkon H, Melamed E, Offen D. 2001. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol 21: 771-781.
18. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Capobianco L, de Blasi A, Battaglia G, Nicoletti F, Ruggieri S, Paparelli A. 2004. Similarities between methamphetamine toxicity and proteasome inhibition. Ann NY Acad Sci 1025: 162-170.
19. Fornstedt B, Rosengren E, Carlsson A. 1986. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25: 451-454.
20. Franklin KBJ, Paxinos G. 1997. The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
21. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. 2002. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem 81: 1285-1297.
22. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643.
23. Haque ME, Asanuma M, Higashi Y, Miyazaki I, Tanaka K, Ogawa N. 2003a. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 1619: 39-52.
24. Haque ME, Asanuma M, Higashi Y, Miyazaki I, Tanaka K, Ogawa N. 2003b. Overexpression of Cu-Zn superoxide dismutase protects neuroblastoma cells against dopamine cytotoxicity accompanied by increase in their glutathione level. Neurosci Res 47: 31-37.
25. Hoglinger GU, Carrard G, Michel PP, Medja F, Lombes A, Ruberg M, Friguet B, Hirsch EC. 2003. Dysfunction of mitochondrial complex I, the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86: 1297-1307.
26. Holloway AF, Stennard FA, Dziegielewska KM, Weller L, West AK. 1997. Localisation and expression of metallothionein immunoreactivity in the developing sheep brain. Int J Dev Neurosci 15: 195-203.
27. Hussain S, Slikker WJr, Ali SF. 1996. Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in neuroprotection. Neurochem Int 29: 145-152.
28. Iwata-Ichikawa E, Kondo Y, Miyazaki I, Asanuma M, Ogawa N. 1999. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J Neurochem 72: 2334-2344.
29. Kita T, Wagner GC, Nakashima T. 2003. Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption. J Pharmacol Sci 92: 178-195.
30. Kohler LB, Berezin V, Bock E, Penkowa M. 2003. The role of metallothionein II in neuronal differentiation and survival. Brain Res 992: 128-136.
31. Kuhn DM, Arthur REJr, Thomas DM, Elferink LA. 1999. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem 73: 1309-1317.
32. Lai CT, Yu PH. 1997. Dopamine- and L-b-3, 4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 53: 363-372.
33. LaVoie MJ, Hastings TG. 1999. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. J Neurosci 19: 1484-1491.
34. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. 2005. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11: 1214-1221.
35. Lee SY, Moon Y, Hee Choi D, Jin Choi H, Hwang O. 2007. Particular vulnerability of rat mesencephalic dopaminergic neurons to tetrahydrobiopterin: Relevance to Parkinson's disease. Neurobiol Dis 25: 112-120.
36. Makar TK, Nedergaard M, Preuss A, Gelbard AS, Perumal AS, Cooper AJ. 1994. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: Evidence that astrocytes play an important role in antioxidative processes in the brain. J Neurochem 62: 45-53.
37. Miyazaki I, Asanuma M. 2008. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 62: 141-150.
38. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, Ogawa N. 2006. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules. FASEB J 20: 571-573.
39. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Miyoshi K, Ogawa N. 2005. Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro. Clin Neuropharmacol 28: 155-160.
40. Miyazaki I, Asanuma M, Higashi Y, Sogawa CA, Tanaka K, Ogawa N. 2002. Age-related changes in expression of metallothionein-III in rat brain. Neurosci Res 43: 323-333.
41. Miyazaki I, Asanuma M, Hozumi H, Miyoshi K, Sogawa N. 2007. Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity. FEBS Lett 581: 5003-5008.
42. Mocchegiani E, Muzzioli M, Giacconi R. 2000. Zinc and immunoresistance to infection in aging: new biological tools. Trends Pharmacol Sci 21: 205-208.
43. Offen D, Ziv I, Sternin H, Melamed E, Hochman A. 1996. Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease. Exp Neurol 141: 32-39.
44. Palmiter RD. 1998. The elusive function of metallothioneins. Proc Natl Acad Sci USA 95: 8428-8430.
45. Paz MA, Fluckiger R, Boak A, Kagan HM, Gallop PM. 1991. Specific detection of quinoproteins by redox-cycling staining. J Biol Chem 266: 689-692.
46. Penkowa M. 2006. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J 273: 1857-1870.
47. Radtke F, Heuchel R, Georgiev O, Hergersberg M, Gariglio M, Dembic Z, Schaffner W. 1993. Cloned transcription factor MTF-1 activates the mouse metallothionein I promoter. EMBO J 12: 1355-1362.
48. Shih AY, Erb H, Murphy TH. 2007. Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells. J Neurochem 101: 109-119.
49. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH. 2003. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23: 3394-3406.
50. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L. 2000. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 97: 11869-11874.
51. Sulzer D, Zecca L. 2000. Intraneuronal dopamine-quinone synthesis: A review. Neurotox Res 1: 181-195.
52. Thornalley PJ, Vasak M. 1985. Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim Biophys Acta 827: 36-44.
53. Tse DC, McCreery RL, Adams RN. 1976. Potential oxidative pathways of brain catecholamines. J Med Chem 19: 37-40.
54. Whitehead RE, Ferrer JV, Javitch JA, Justice JB. 2001. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 76: 1242-1251.